NCT06723171暂停2 期
A 4-Week, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of the RXR Agonist Compound IRX4204 for the Treatment of Mild to Moderate Plaque Psoriasis
Io Therapeutics1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2026年3月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 暂停
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- To evaluate if participants receiving IRX4204 achieve greater reduction in IGA scores when compared to participants receiving placebo
研究概览
简要总结
The goal of this clinical trial is to learn if IRX4204 works to treat plaque psoriasis in adults. It will also learn about the safety of IRX4204. The main questions it aims to answer are:
- Does IRX4204 treat plaque psoriasis symptoms?
- Does IRX4204 treat plaque psoriasis symptoms better than someone who is not being treated?
- What medical problems do participants have when taking IRX4204?
Researchers will compare IRX4204 to a placebo (a look-alike substance that contains no drug) to see if the drug works to treat mild to moderate plaque psoriasis.
Participants will:
- Take IRX4204 every day for 28 days
- Visit the clinic once every week for checkups and tests
- Complete specific assessments about plaque psoriasis and changes to plaques
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years of age
- •Have a diagnosis of plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study treatment
- •Meet the following disease severity criteria for moderate to severe plaque psoriasis at Screening and Baseline visits:
- •IGA Score of 3 or 4 AND
- •Total affected body surface area of >3 to 10% for moderate and 10% to 15% for severe psoriasis
- •Excludes participants with scalp only plaques
- •Be inadequately controlled with or intolerant of at least one prior topical therapy including but not limited to: corticosteroids, retinoids, vitamin D, vitamin D/steroid and retinoid/steroid combinations, tacrolimus, pimecrolimus, anthralin/dithranol, coal tar preparations, tapinarof, roflumilast for the treatment of psoriasis at both Screening and Baseline visits
- •In the opinion of the Investigator, be a candidate for phototherapy or systemic treatment for psoriasis
- •Completed appropriate washouts for prior treatments for psoriasis
- •Be considered, in the opinion of the Investigator, suitable candidates for RXR agonist therapy
- •Women participants of childbearing potential (WOCBP) (see Section 8.1.10) or sexually active male participants with partners of childbearing potential agree to practice a highly effective method of contraception (failure rate of < 1% per year when used consistently and correctly; see Section 8.1.10.1) prior to receiving, while receiving, and for at least 6 months after receiving the last administration of study intervention
- •WOCBP must have a negative highly sensitive serum beta-human chorionic gonadotropic (b-hCG) pregnancy test at Screening and confirmed at Baseline prior to receiving the first administration of study drug
- •WOCBP must agree not to donate eggs (ova, oocytes) or freeze for future and males must agree not to donate sperm for the purpose of reproduction for at least 6 months after receiving the last administration of study intervention.
- •Female participants must agree to not breastfeed while enrolled in this study and within 6 months after the last dose of study intervention
- •Sign an informed consent form (ICF) indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study
- •Be willing to and able to adhere to the requirements in this protocol
排除标准
- •Has more than 15% of total body surface area affected by psoriasis plaques
- •Has a non-plaque form of psoriasis (e.g., erythrodermic, guttate, or pustular) at Screening or at time of randomization
- •Has current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta-blockers, calcium channel blockers, or lithium)
- •Has confounding diagnoses including but not limited to palmoplantar pustulosis, eczematous dermatitis, contact/irritant dermatitis, acquired keratoderma
- •Has received within 12 weeks of the first dose (Day 1) any prior biologic (or biosimilars of) for the treatment of psoriasis, psoriatic arthritis, or any other indications that could impact the assessment of psoriasis. Prior biologic therapy includes but is not limited to TNF-inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, IL-23 inhibitors
- •Has received within 4 weeks of the first dose (Day 1) any systemic immunosuppressives for the treatment of psoriasis or psoriatic arthritis, or any other indications that could impact the assessment of psoriasis, Phototherapy or narrow band laser (e.g., Excimer or XTRAC), lithium, antimalarials, or intramuscular (IM) gold. Systemic immunosuppressive therapy includes but is not limited to methotrexate, azathioprine, cyclosporine, JAK/TYK pathway inhibitors, 6-thioguanine, mercaptopurine, mycophenolate mofetil, tacrolimus, acitretin, or anakinra
- •Has received within 2 weeks of the first dose (Day 1) any topical medications for psoriasis or other conditions that could impact assessment of psoriasis, including but not limited to topical corticosteroids, retinoids, vitamin D analogs, combinations of calcipotriene and topical corticosteroids, tacrolimus, pimecrolimus, anthralin/dithranol, coal tar preparations, PDE4 inhibitors (e.g. crisaborole), or other topicals used for the treatment of psoriasis (tapinarof, roflumilast etc.)
- •Has received within 12 weeks or 5 half-lives (whichever is longer) of the first dose (Day 1) other biologic therapy or experimental antibody, any agent that modulates T-cells (e.g., natalizumab, abatacept etc.)
- •Has received within 4 weeks or 5 half-lives (whichever is longer) of the first dose (Day 1) any other experimental systemic therapy for any indication
- •Is currently enrolled in another study using an investigational agent or procedure
- •Has evidence of skin conditions that could interfere with clinical assessments of psoriasis (e.g. eczema, seborrheic dermatitis, or pityriasis rosea)
- •Has a current history of severe, uncontrolled or progressive systemic medical conditions including renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- •Has unstable cardiovascular disease, defined as a recent clinical deterioration in the last 3 months (e.g., unstable angina, atrial fibrillation) or a cardiac hospitalization within the last 3 months
- •Currently has a known malignancy or has a history of malignancy within 5 years before screening with the exception of non-melanoma skin cancer curatively treated with no evidence of recurrence for at least 3 months before the first study drug administration or cervical carcinoma in situ of the cervix that has been treated with no evidence of recurrence for at least 3 years before the first study drug administration
- •Has a history of lymphoproliferative disease, including lymphoma, leukemia, monoclonal gammopathy, or signs/symptoms suggestive of possible lymphoproliferative disease
- •Has a transplanted organ (with the exception of a corneal transplant > 3 months before the first study drug administration)
- •Has unstable suicidal ideation or suicidal behavior, or a suicide attempt (including interrupted, aborted attempts and preparatory behaviors for suicide attempt), in the last 6 months
- •Has had a major surgery within 8 weeks of Screening or has such surgery planned during the time participant is expected to participate in the study
- •Has had a substance abuse problem within the previous 12 months
- •Has a history of chronic or recurrent infectious disease including but not limited to chronic renal infection, recurrent urinary tract infection (UTI), chronic respiratory infections (e.g., tuberculosis), skin infections, or fungal infections
- •Is currently being treated for a thyroid condition or have abnormalities in TSH, free T4 or T3 at Screening
- •Has had a serious infection (e.g., sepsis, pneumonia, pyelonephritis) requiring hospitalization within the 2 months before Screening
- •Has had herpes zoster (shingles) within 2 months prior to Screening
- •Has an active tuberculosis (TB) infection as confirmed by TB test during screening
- •Tests positive for hepatitis B virus (HBV) infection
- •Is seropositive for antibodies to hepatitis C virus (HCV). If the antibody test result is positive at screening, the participant will be allowed to be re-screened one time and enrolled after a negative HCV RNA test result
- •Is infected with human immunodeficiency virus (HIV)
- •Unable to avoid prolonged sun exposure or use of tanning beds or other ultraviolet light sources
- •Has received within 2 weeks of the first dose (Day 1) any prescribed anticoagulant, including but not limited to coumarins (such as warfarin), factor Xa inhibitors (i.e., apixaban, rivaroxaban), heparins (e.g., heparin, enoxaparin), and direct thrombin inhibitors
- •Has any condition that, in the opinion of the Investigator, would make participation not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments
- •Is an employee of the Investigator or study site, with direct involvement in the proposed study or other studies under the direction of that Investigator or study site, as well as family members of the employees or the Investigator
- •Any abnormal laboratory value greater than 2.5 times upper limit of normal (ULN). If one or more of the laboratory parameters is out of range, a single retest of laboratory values is permitted
研究组 & 干预措施
Treatment
Active Comparator
IRX4204
干预措施: IRX4204 (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Other)
结局指标
主要结局
To evaluate if participants receiving IRX4204 achieve greater reduction in IGA scores when compared to participants receiving placebo
时间窗: Baseline (Day 1) to Day 42
Percentage of participants achieving an Investigator's Global Assessment (IGA) score of clear (0) or almost clear (1) at Day 28 with at least a 2-grade improvement from Baseline to end of study.
次要结局
- To evaluate if participants receiving IRX4204 have greater improvement in participant reported outcomes when compared to participants receiving placebo(from Baseline (Day 1) to Day 28)
- To evaluate if participants receiving IRX4204 experience a greater reduction in affected Body Surface Area when compared to participants receiving placebo(from Baseline (Day 1) to Day 28)
- To evaluate if a greater proportion of participants receiving IRX4204 achieve PASI50, PASI75 and PASI90 when compared to participants receiving placebo(from Baseline (Day 1) to End of Study (Day 42))
- To evaluate if participants receiving IRX4204 achieve greater improvement from baseline in disease and symptom severity as measured by the Psoriasis Area and Severity Index (PASI).(from Baseline (Day 1) to End of Treatment (Day 28))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body PsoriasisPsoriasisNCT01139580Stiefel, a GSK Company363
已完成
2 期
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With PsoriasisPsoriasisNCT01837420Vascular Biogenics Ltd. operating as VBL Therapeutics194
已完成
2 期
A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque PsoriasisPlaque PsoriasisNCT01634087Incyte Corporation50
Unknown
1 期
Safety and Efficacy of UC-MSCs in Patients With Plaque PsoriasisModerate and Severe Plaque PsoriasisNCT03424629Tianjin Ever Union Biotechnology Co., Ltd.57
终止
1 期
Study to Determine if AZD0284 is Effective and Safe in Treating Plaque PsoriasisPlaque Psoriasis VulgarisNCT03310320AstraZeneca9